XSHE
002932
Market cap481mUSD
Jul 10, Last price
14.30CNY
1D
1.78%
1Q
-14.27%
IPO
24.67%
Name
Wuhan Easy Diagnosis Biomedicine Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. specializes in the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) reagents and related equipment. Their extensive product line features molecular diagnostics, including genetic tests for drug metabolism and pathogen nucleic acid detection kits, alongside immunodiagnostic and blood gas analysis solutions. Beyond diagnostics, the company delivers comprehensive information solutions for emergency and critical illness, which encompass specialized software, supporting hardware, and expert certification consulting. They also provide third-party medical testing services. These offerings are applied across a broad spectrum of medical fields, addressing conditions such as cardiovascular, kidney, infectious, diabetes, endocrine, and metabolic diseases, as well as obstetrics and gynecology. Furthermore, their products support prenatal and postnatal care, general health check-ups, and specific analyses for thyroid function, hormones, blood gases, coagulation, drug metabolism, and pathogen identification. Established in 2008, the company is headquartered in Wuhan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||